Printer Friendly

ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992

 MINNEAPOLIS, Feb. 11 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) today announced operating results for the first quarter ended Dec. 31, 1992. The company recognized net income of $527,500, or $0.02 per share, compared with a net loss of $424,288, or ($0.02) per share, in the year-ago period. Revenues for the first quarter were $2,262,941 compared with $933,041 for the first quarter ended Dec. 31, 1991. Current-year revenues included a $1.5 million initial licensing fee from Tecnomara AG of Switzerland. The licensing fee along with ongoing royalty revenues gives Tecnomara AG the exclusive worldwide rights to manufacture and market the Acumouse(TM) cell culture system for use in the area of research.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, Inc., commented: "We were pleased to have completed the license agreement for the Acumouse with Tecnomara AG. Aside from the financial benefits of the transaction, this strategic agreement with Tecnomara, in effect, creates a strong marketing partner for Endotronics with the resources and experience necessary to reach the large U.S. research market."
 "Although we experienced a decline in instrument sales this period, this was partially offset by initial sales of the company's Opticell(R) product line and sales of our HeLaPure(TM) research reagent products."
 Sakowicz went on to say, "We also experienced increased sales from our contract production business this quarter. In January, we were pleased to announce that we upgraded our contract production facility to offer contract production capability to manufacture clinical grade, injectable biopharmaceuticals and biodiagnostics. We expect these new products and services to play an important part in the overall growth of the company, consolidating our market leadership position and furthering our objective to become 'The Cell Culture Company(TM).'"
 ENDOTRONICS, INC.
 CONDENSED STATEMENTS OF OPERATIONS
 Three Months Ended Dec. 31,
 Unaudited
 1992 1991
 Operating revenues $2,262,941 $933,041
 Operating income (loss) $645,034 ($370,395)
 Net income (loss) $527,500 ($424,288)
 Net income (loss) per share
 of common stock $0.02 ($0.02)
 Weighted average no. of
 common shares outstanding 23,212,324 18,651,674
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized industry leader in mammalian cell culture instrumentation with more than 700 research/pilot scale and over 100 production scale instruments sold worldwide since 1986.
 -0- 2/11/93
 /CONTACT: Yvonne L. Marschner-Bova, director, investor relations, Endotronics, Inc., 313-871-7350/
 (ENDO)


CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: ERN

SB-ML -- DE013 -- 5602 02/11/93 10:26 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1993
Words:441
Previous Article:BUDD ANNOUNCES $10 MILLION WHEEL/BRAKE ORDER FOR NEW LIGHTWEIGHT SYSTEM
Next Article:MOVIE STAR REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
ENDOTRONICS, INC. REPORTS FOURTH-QUARTER PROFIT, LOSS FOR YEAR
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM
ENDOTRONICS, INC. REPORTS SECOND-QUARTER AND SIX-MONTHS RESULTS
ENDOTRONICS, INC. ANNOUNCES PURCHASE OF OPTICELL(TM) CELL CULTURE PRODUCT LINE FROM CHARLES RIVER LABORATORIES
ENDOTRONICS, INC. ANNOUNCES RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED JUNE 30, 1992
ENDOTRONICS, INC. SIGNS STRATEGIC COOPERATION AGREEMENT WITH TECNOMARA AG OF SWITZERLAND
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters